DNDi trial raises prospect of cut-price HCV drugs in Malaysia
The Drugs for Neglected Diseases initiative (DNDi) says results from its Phase II/III STORM-C-1 trial of a sofosbuvir/ravidasvir combination, produced by Egyptian generic drugmaker Pharco Pharmaceuticals, shows the hepatitis C therapy to be “safe and effective, with extremely high cure rates for patients, including hard-to-treat cases.”
Founded in 2003, the Geneva-based non-profit conducts its own clinical development programs drawing from a mix of public and private donations. The group has a pipeline of over 30 projects targeting some of the world’s most neglected diseases.
In accordance with international standards defining cure for HCV treatments, 12 weeks after treatment completion, 97% of those enrolled were cured, and no new safety signals were detected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze